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Abstract
We compared the cost-effectiveness of a methicillin-resistant Staphylococcus aureus (MRSA) programme of active surveillance plus decol-
onization with the current Veterans Health Administration (VHA) strategy of active surveillance alone, as well as a common strategy of
no surveillance. A decision-analytical model was developed for an inpatient stay time horizon, using the VHA’s perspective. Model inputs
were taken from published literature where available, and supplemented with expert opinion when necessary. Effectiveness outcomes
were hospital-acquired MRSA infections and deaths avoided. One-way and two-way sensitivity analyses and Monte Carlo simulations
were performed. In the base-case analysis, the strategy of active surveillance plus decolonization dominated (i.e. lower cost and greater
effectiveness) both the comparison strategies of active surveillance and no surveillance. In addition, the active surveillance strategy domi-
nated the strategy of no surveillance. One-way and two-way sensitivity analyses demonstrated that at low levels of direct beneﬁt of
decolonization (1–4%), the strategy of active surveillance plus decolonization would no longer be dominant. In the probabilistic sensitiv-
ity analysis, active surveillance plus decolonization dominated both the other two strategies, and the active surveillance strategy domi-
nated no surveillance in all of 1000 Monte Carlo simulations. These results provide a strong economic argument for adding an MRSA
decolonization protocol to the current VHA active surveillance strategy.
Keywords: Active surveillance, chlorhexidine, cost-effectiveness analysis, decolonization, MRSA, mupirocin
Original Submission: 26 April 2010; Revised Submission: 12 July 2010; Accepted: 14 July 2010
Editor: M. Paul
Article published online: 29 July 2010
Clin Microbiol Infect 2010; 16: 1740–1746
Corresponding author: R. E. Nelson, George E. Whalen Depart-
ment of Veterans Affairs Medical Center, 500 Foothill Drive,
GRECC-182, Salt Lake City, UT 84148, USA
E-mail: Richard.Nelson@utah.edu
Introduction
Healthcare-associated infections (HAIs) are a signiﬁcant bur-
den on both patients and healthcare systems in the USA [1].
This is true in Europe as well, where HAIs are associated
with roughly €7 billion in annual direct costs [2]. Among the
most common organisms causing HAIs is methicillin-resistant
Staphylococcus aureus (MRSA), which is often transmitted by
asymptomatic carriers. Carriage of MRSA signiﬁcantly
increases infection risk among inpatients [3]. Laws in the UK
and several states in the USA now mandate MRSA screening
for certain patients upon hospital admission. Similar hospital-
speciﬁc programmes have been implemented in many
locations, including Switzerland [4] and the VA Pittsburgh
Healthcare System. This latter programme proved successful,
with a 60% reduction in MRSA infections [5], leading the
Veterans Health Administration (VHA) to expand this policy
to all VHA facilities in 2007 as part of the National VHA
MRSA Prevention Initiative.
As per this policy, all patients admitted to a VHA facility
are screened for MRSA colonization with a nasal swab;
detected MRSA carriers are then subjected to contact pre-
cautions. Decolonization, through topical treatment such as
mupirocin or chlorhexidine bathing, is an additional MRSA
control strategy that could be implemented in conjunction
with isolation [6]. Both universal screening and isolation and
decolonization incur implementation costs, which might be
offset by decreased infection risk and improved patient out-
comes. However, despite widespread usage, relatively little is
known about the cost-effectiveness of these strategies. Sev-
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eral studies have examined the cost and outcomes of screen-
ing and isolation strategies in speciﬁc wards within a hospital
[7,8]. Other cost-effectiveness studies have examined a
variety of screening strategies [9], as well as mupirocin alone
in surgical [10] and haemodialysis [11] patients.
We developed a decision-analytical model to compare the
clinical outcomes and the economic costs associated with
several MRSA control strategies implemented at the facility
level. Speciﬁcally, we compared three different strategies:
active surveillance (AS) plus decolonization (AS + D), the
current VHA strategy of AS alone, and no surveillance (NS),
which is the strategy employed at many non-VHA hospitals
in the USA. All patients in hospitals with MRSA-colonized
patients are at risk for an infection caused by transmission.
A unique aspect of this study is an exploration of the indi-
rect beneﬁt of decolonization (the reduction in risk of infec-
tion in non-colonized patients in hospitals that use the
decolonization strategy).
Methods
Model structure
The model, depicted in Fig. 1, was programmed in Microsoft
Excel and TreeAge Pro 2009. It was constructed using the
healthcare deliverer’s (i.e. the VHA’s) perspective, and was
evaluated with an inpatient hospital stay as the time horizon.
Outcomes from the model included costs (such as those
associated with MRSA infection, decolonization, isolation,
and screening), as well as nosocomial MRSA infections and
infection-related deaths avoided. The model was run sepa-
rately for each effectiveness measure. Patients entered the
model by being admitted to the hospital. The facility to
which each patient was admitted used a strategy of either
AS + D, AS, or NS, and costs and outcomes were compared
between these three strategies. Regardless of which facility
was entered, patients could be either a carrier or non-car-
rier of MRSA at the time of admission. Patients in either an
AS + D or AS facility were then screened for MRSA car-
riage, with the indicated measures taken for those who
tested positive for MRSA. Our model did not assume that
patients in NS hospitals who were known to be colonized
with MRSA would be isolated. Finally, patients in all three
facilities were at risk for developing a hospital-acquired
MRSA infection, which carried with it a risk for mortality.
Input parameters
The model was populated with input parameters taken from
published literature. However, an authors’ assumption had to
be used in the case of the indirect beneﬁt of decolonization,
because no adequate published article could be found. These
parameters are deﬁned in Table 1 and are explained here by
category.
Event probabilities. Base-case event probabilities were deter-
mined, as well as a plausible range to be used in the sensitiv-
ity analyses. We estimated the admission prevalence of
MRSA, based on a number of published studies, to be 7.5%,
with a range of 4.5–12.8% [12–15]. Sensitivity and speciﬁcity
of PCR screening were estimated to be 94.6% (range: 90–
98%) and 96.9% (range: 90–98%), respectively [16]. The risks
of MRSA infection were 12.8% (range: 7.8–17.8%) in carriers
[14,15,17] and 6.6% (range: 1.6–11.6%) in non-carriers [14].
The reduction in the risk of MRSA infection among individu-
als who are decolonized (referred to here as the ‘direct ben-
eﬁt of decolonization’) was 30% (range: 8–75%) [18]. We
Death
AS+D MRSA carrier Screen positive
MRSA HAI
No Death
Patient admitted to hospital AS MRSA non-carrier Screen negative
MRSA carrier
No MRSA HAI
NS
MRSA non-carrier
FIG. 1. Decision-analytical model. Branches extending from the square-shaped decision node represent each of the surveillance strategies being
compared; circle-shaped nodes are called chance nodes; event-speciﬁc probabilities listed in Table 1 determine which branch is followed from a
chance node; triangle-shaped nodes are called terminal nodes and indicate the end of a pathway. AS + D, active surveillance with decolonization.
AS, active surveillance; NS, no surveillance; HAI, healthcare-associated infection; MRSA, methicillin-resistant Staphylococcus aureus.
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were unable to ﬁnd any published estimates of MRSA infec-
tion risk reduction among patients who are not decolonized
but are admitted to a facility that employs an MRSA decolo-
nization policy; this beneﬁt, which we refer to as the ‘indi-
rect beneﬁt of decolonization’ [19], was assumed to be 33%
(range: 28–38%) of the direct beneﬁt. The beneﬁt of isolation
was identiﬁed from the literature as a 33% (range: 28–38%)
reduction in risk of MRSA HAI [20,21]. Neither of the
published articles from which this value was taken
distinguished between isolated and non-isolated patients
when reporting their MRSA HAI reductions attributable to
isolation and contact precautions. We assumed that this ben-
eﬁt was entirely indirect (i.e. only enjoyed by non-isolated
patients). Finally, the risk of death resulting from any type of
MRSA infection was estimated to be 10% (range: 1–30%)
[17,22].
Costs. The literature-based cost estimate of nasal screening
with PCR was $50 (range: $20 to $80) [23]. The cost of
decolonization was calculated from the cost of topical
treatment with mupirocin ointment, obtained from the VA
Salt Lake City ($10), chlorhexidine showers ($5) [24], and
30 min of a nurse’s time to administer the treatment. An
hourly wage of $30, obtained from the US Bureau of Labor
Statistics, was used to quantify the cost of a nurse’s time.
To calculate the isolation costs, we assumed that, as com-
pared with a non-isolated patient, an isolated patient would
receive an extra nurse visit every 2 h (for a total of 12 per
day) and an extra two physician visits per day. Assuming
that each of these visits lasts 10 min, and that the hourly
wage for a physician is $75 (also obtained from the US
Bureau of Labor Statistics), the total cost of extra nurse
and physician time attributable to isolation was calculated
to be $85 per patient per day. During each visit, nurses
and physicians will use a pair of gloves (seven cents) and a
gown (75 cents) [25]. Assuming an average length of stay of
5 days [26], we calculated the total cost of isolation as
$482.40 per admitted patient. These isolation costs were
relevant to patients who tested positive in both AS and
AS + D facilities.
The ﬁnal cost input is for MRSA HAI. Although there is
considerable dispute about this value in the published litera-
ture, we chose a base-case value of $20 000 [27]. However,
there are suggestions that this value might be much higher
[22]. Higher values (as well as lower ones) were explored in
our sensitivity analyses.
Outcomes. We utilized two alternative effectiveness out-
comes: nosocomial MRSA infections avoided, and infection-
related deaths avoided. These outcomes have been used in
similar analyses [7].
Sensitivity analysis
One-way sensitivity analyses were performed for each
input, and are presented as a threshold analysis, in which
the threshold value of a particular input at which AS + D
no longer dominates is reported. We also performed two-
way sensitivity analyses with several important inputs: (i)
risk and cost of hospital-acquired MRSA infection; (ii) direct
and indirect beneﬁts of decolonization; (iii) direct beneﬁts
of decolonization and risk of hospital-acquired MRSA infec-
tion; and (iv) direct beneﬁts of decolonization and cost of
hospital-acquired MRSA infection. The inputs considered
in these two-way sensitivity analyses were chosen
either because of lack of consensus on their values in the
literature, or because of the possibility that they may
change over time. Finally, probabilistic sensitivity analyses
were performed in which all parameters were varied at
TABLE 1. Model inputs
Variable Base case Range Distribution Source
Probability inputs (%)
Admission prevalence of MRSA 7.5 4.5–12.8 Beta [12–15]
Sensitivity of screening 94.6 90–98 Beta [16]
Speciﬁcity of screening 96.9 90–98 Beta [16]
Risk of MRSA infection in carriers 12.8 7.8–17.8 Beta [14,15,17]
Risk of MRSA infection in non-carriers 6.6 1.6–11.6 Beta [14]
Direct beneﬁt of decolonization 45 8–75 Beta [14]
Indirect beneﬁt of decolonization
(% of direct beneﬁt)
33 28–38 Beta Assumption
Indirect beneﬁt of isolation 33 28–38 Beta [20,21]
Probability of death resulting from
to MRSA infection
10 1–30 Beta [17,22]
Costs ($)
Screening 50 25–100 Gamma [23]
Decolonization 30 15–60 Gamma Local costs [24]
Isolation 482 319–531 Gamma [25,26]
MRSA infection 20 000 10 000–100 000 Gamma [22]
MRSA, methicillin-resistant Staphylococcus aureus.
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once. The distributions chosen for each input are shown in
Table 1.
Results
The base-case results from the model using both effective-
ness outcomes, infections and deaths avoided, are presented
in Table 2. Both the costs and effectiveness outcomes (per
100 patients) of each of the three surveillance strategies
(AS + D, AS, and NS) were compared with each other. As
compared with both of the other options, AS + D was asso-
ciated with lower average costs as well as more infections
and deaths avoided. This means that AS + D dominates
(i.e. has lower costs and is more effective) the other two
alternatives. Additionally, when compared to NS, AS is also
dominant.
Sensitivity analysis
The results of the threshold analyses, performed on each input
to the model, are shown in Table 2, along with the ranges
used. Only three inputs had values for which AS + D was no
longer the dominant strategy: risk of hospital-acquired MRSA
infection in non-carriers, direct beneﬁt of decolonization, and
cost of hospital-acquired MRSA infection. The values for which
the dominance thresholds were crossed were at the low end
of the ranges explored. The dominant strategies beyond this
threshold were AS for the case of direct beneﬁt of decoloniza-
tion and NS for the other two inputs.
Fig. 2a shows the results of the two-way sensitivity
analysis of the risk of hospital-acquired MRSA infections in
carriers and the cost of such an infection. It shows that, for
infection costs above about $3000, AS + D remains the
dominant strategy. However, when these costs fall below
this $3000 value, the dominant strategy is NS. Fig. 2b,c
shows similar analyses for direct and indirect beneﬁts of
decolonization and direct beneﬁts of decolonization and
risk of hospital-acquired MRSA infection in carriers, respec-
tively. It can be seen that AS + D is the dominant strategy
unless the direct beneﬁt is extremely low. If this is the case,
then AS is the dominant strategy. Finally, Fig. 2d gives the
results from a two-way sensitivity analysis of the direct bene-
ﬁt of decolonization and the cost of hospital-acquired MRSA
infection, and shows that, for low values for the cost of
infection, the NS strategy dominates. It also shows that, for
low levels of direct beneﬁt of decolonization, the AS strategy
TABLE 2. (a) base-case results (per 100 patients); (b) threshold analysis
(a) Base-case results
Strategy Cost ($)
Incremental
cost ($) Effectiveness
Incremental
effectiveness
Incremental
cost-effectiveness ratio
MRSA infections avoided
AS + D 93 538 – 96.07 – –
AS 107 971 14 433 95.69 – 0.38 Dominated
NS 141 300 47 762 92.94 – 3.13 Dominated
Infection-related deaths avoided
AS + D 93 538 – 99.57 – –
AS 107 971 14 433 99.49 ) 0.08 Dominated
NS 141 300 47 762 99.29 ) 0.28 Dominated
(b) Threshold analysis
Variable Range Threshold
Dominant
strategy
Probability inputs (%)
Admission prevalence of MRSA 0–30 None –
Sensitivity of screening 60–98 None –
Speciﬁcity of screening 60–98 None –
Risk of MRSA infection in carriers 0–50 None –
Risk of MRSA infection in non-carriers 0–50 0% NS
Direct beneﬁt of decolonization 0–100 1% AS
Indirect beneﬁt of decolonization (% of direct beneﬁt) 0–60 None –
Indirect beneﬁt of isolation 0–50 None –
Probability of death resulting from to MRSA infection 1–30 None –
Cost inputs ($)
Screening 10–200 None –
Decolonization 0–200 None –
Isolation 0–800 None –
MRSA infection 0–100 000 2768 NS
AS, active surveillance; AS + D, active surveillance plus decolonization; MRSA, methicillin-resistant Staphylococcus aureus; NS, no surveillance.
Threshold indicates the value of the input at which AS + D is no longer the dominant strategy.
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dominates. However, for all other values of both variables,
AS + D dominates.
We performed probabilistic sensitivity analyses for the
infections avoided and deaths avoided outcomes. In all 1000
stimulations comparing AS + D with either AD or ND,
AS + D remained the dominant strategy.
Discussion
The results from this analysis support the notion that
AS + D is overwhelmingly cost-effective as compared with
either AS or NS. In fact, AS + D dominated (i.e. was
cost-saving and more effective in comparison with) the two
alternative strategies. This was true for both effectiveness
measures: infections avoided and deaths avoided. The domi-
nance of AS + D is probably attributable to the low cost of
topical mupirocin and chlorhexidine treatment as compared
with the high excess cost of a nosocomial MRSA infection.
This economic analysis of three different strategies of
combating MRSA HAIs in a hospital setting can help policy-
makers trying to decide on an effective strategy. Since the
adoption of the VHA’s National MRSA Prevention Initiative,
a nascent literature has arisen evaluating the effectiveness of
a strategy of AS [7,8,28]. Our study contributes to this liter-
ature by not only evaluating an AS strategy in comparison
with the common strategy of NS, but also by comparing a
proposed extension to the AS strategy. Our results suggest
that the VHA’s current strategy of isolation alone probably
leads to fewer MRSA infections and MRSA infection-related
deaths, as well as lower average costs per patient, than the
common strategy of no isolation. However, we also show
that adding decolonization to the current AS strategy, in
which patients are only isolated, would potentially be more
effective at reducing MRSA infections, as well as reducing the
average cost per patient, than simple isolation alone.
Several inputs to this decision tree were unavailable from
existing literature. For instance, as a static cohort model,
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FIG. 2. Two-way sensitivity analyses. AS + D, active surveillance with decolonization. AS, active surveillance; NS, no surveillance; HAI, health-
care-associated infection; MRSA, methicillin-resistant Staphylococcus aureus.
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our analysis was unable to incorporate the many dynamic
aspects of MRSA and its treatments. Over time, decoloniza-
tion treatments can become less effective, because of resis-
tance acquired by the pathogens targeted by the treatment
[29]. Although a dynamic model is the best way to incorpo-
rate resistance over time into a cost-effectiveness analysis,
we modelled the effect of increasing resistance by perform-
ing a one-way sensitivity analysis, and several two-way sensi-
tivity analyses, to determine the threshold of effectiveness of
decolonization at which AS + D would no longer be the
dominant strategy. This threshold was an effectiveness level
of 1% in the one-way sensitivity analysis (Table 2) and
between 1% and 4% in the two-way sensitivity analyses.
However, depending on the decision-maker’s willingness to
pay, AS + D may continue to be cost-effective as compared
with alternative strategies at effectiveness levels less than
these threshold levels.
Our ﬁndings are consistent with several other published
economic evaluations, which found that a strategy of AS + D
was cost-saving as compared with NS in selected surgical
patients [8,10]. Our study expands on this previous research
by considering all patients admitted to a hospital, as well as
by including outcome measures as well as costs. Our results
differ from those of a recent study, which found that univer-
sal AS with rapid PCR was not cost-effective as compared
with NS for patients admitted to surgery in a large Swiss
hospital [7]. This discrepancy may be attributable to the dif-
ferences in on-admission MRSA prevalence, nosocomial
MRSA infection and transmission rates, compliance with basic
hygiene measures, and attributable costs of MRSA infection.
The beneﬁts of decolonization have been questioned,
because of the high risk of recolonization [18]. Our goal in
this analysis, however, was to measure the short-term
impact of decolonization in a well-deﬁned time period: dur-
ing an inpatient hospital stay. To obtain a broader picture,
future work should address the issue of recolonization and
re-admission of previously decolonized individuals.
Our study has several limitations. First, as described
above, our static cohort model is not equipped to capture
the dynamic elements of decolonization, including resistance,
compliance with contact precaution protocol, and herd
immunity effects. Second, infections can vary greatly with
type, source, and severity. It is therefore difﬁcult to accu-
rately quantify the utility associated with an infection.
Because of this, our effectiveness measures were infections
and deaths avoided rather than quality-adjusted life-years.
Future studies will aim to separate infections by a number of
characteristics in order to gain a greater understanding of
the speciﬁc effects of decolonization on patients’ wellbeing.
Finally, the time interval between test and result was not
explicitly modelled in our decision tree. However, PCR
produces results in just 2–3 h, which is a much faster
turn-around time than the 48–72 h required for conventional
culture and susceptibility testing [30]. Also, delayed initiation
of isolation and decolonization would affect only the indirect
beneﬁt of each of these interventions. We demonstrate the
robustness of our results for various values of indirect bene-
ﬁt through sensitivity analyses.
Conclusion
Our model suggests that adding decolonization to a strategy
of AS would reduce the numbers of both infections and infec-
tion-associated deaths, as well as the average cost per patient,
as compared with either AS alone or with no intervention.
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